- Home
- WDFC vs VRNA Comparison
WDFC vs VRNA Comparison
Compare WDFC & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDFC
- VRNA
- Stock Information
- Founded
- WDFC 1953
- VRNA 2005
- Country
- WDFC United States
- VRNA United Kingdom
- Employees
- WDFC 644
- VRNA N/A
- Industry
- WDFC Major Chemicals
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- WDFC Industrials
- VRNA Health Care
- Exchange
- WDFC Nasdaq
- VRNA Nasdaq
- Market Cap
- WDFC 3.1B
- VRNA 3.4B
- IPO Year
- WDFC N/A
- VRNA 2017
- Fundamental
- Price
- WDFC $229.08
- VRNA $67.96
- Analyst Decision
- WDFC Buy
- VRNA Strong Buy
- Analyst Count
- WDFC 2
- VRNA 7
- Target Price
- WDFC $301.00
- VRNA $57.14
- AVG Volume (30 Days)
- WDFC 78.9K
- VRNA 1.3M
- Earning Date
- WDFC 04-08-2025
- VRNA 02-27-2025
- Dividend Yield
- WDFC 1.63%
- VRNA N/A
- EPS Growth
- WDFC 2.55
- VRNA N/A
- EPS
- WDFC 5.22
- VRNA N/A
- Revenue
- WDFC $603,636,000.00
- VRNA $5,624,000.00
- Revenue This Year
- WDFC $8.31
- VRNA N/A
- Revenue Next Year
- WDFC $6.86
- VRNA $571.44
- P/E Ratio
- WDFC $44.15
- VRNA N/A
- Revenue Growth
- WDFC 9.20
- VRNA 1127.95
- 52 Week Low
- WDFC $211.03
- VRNA $11.39
- 52 Week High
- WDFC $292.36
- VRNA $68.64
- Technical
- Relative Strength Index (RSI)
- WDFC 39.96
- VRNA 76.88
- Support Level
- WDFC $226.73
- VRNA $62.24
- Resistance Level
- WDFC $233.88
- VRNA $65.50
- Average True Range (ATR)
- WDFC 4.80
- VRNA 2.78
- MACD
- WDFC 0.21
- VRNA 0.22
- Stochastic Oscillator
- WDFC 15.78
- VRNA 94.86
About WDFC WD-40 Company
WD-40 Co manufactures and sells lubricants and cleaning products. The firm's product categories include maintenance and cleaning products. Maintenance products include the WD-40 signature brand aerosol spray lubricant as well as degreasers, rust removers, and bicycle maintenance products. Cleaning products include toilet cleaners, carpet stain removers and deodorizers, and heavy-duty hand soaps used to clean grease. The company organizes itself into three segments based on geography: Americas, Europe/Middle East/Africa, and Asia-Pacific. The majority of the company's revenue comes from the Americas segment, which includes the United States, Canada, and Latin America.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.